199 results about "Tumor therapy" patented technology

The disclosure provides a method for treating a subject afflicted with a tumor, e.g., derived from a non-small cell lung cancer (NSCLC), comprising administering to the subject a combination of a (a) chemotherapy, (b) an anti-PD-1 antibody or an anti-PD-L1 antibody, and (c) an anti-CTLA-4 antibody, wherein the chemotherapy is administered for a period of time that is less than the standard.

The application discloses a breast-conserving surgery perforator flap intelligent navigation system and method based on CT three-dimensional blood vessel reconstruction and AI dynamic blood flow analysis, and comprises an image processing module. The image processing module generates a perforator blood vessel three-dimensional model with an accuracy of plus or minus 0.1 mm based on high-resolution CT thin-layer scanning data with a layer thickness of less than or equal to 0.625 mm through Mimics software. The application significantly improves the postoperative outcome of patients through multidimensional technology cooperation. In terms of complication control, the incidence of complications in the donor area is reduced from 22% in the traditional method to 3% (a reduction of 86%), and the expansion of trauma caused by perforator variation is avoided. In terms of aesthetic effect, for the breast-conserving surgery of medial quadrant breast cancer, the lateral thoracic artery perforator flap (LTAP) is combined with AI volume compensation. After the surgery, the postoperative breast upper pole depression rate is reduced from 35% to 5%, the BREAST-Q score of the patient is increased from 68 to 89, the requirements of 'tumor radical treatment' and 'functional aesthetics' are fully considered, the postoperative life quality of the patient is greatly improved, and the humanistic concept of modern tumor treatment is met.

This invention relates to a pharmaceutical composition for tumor treatment and its application. Specifically, this invention relates to a composition containing a fluorouracil drug and pyrimidine nucleosides and their derivatives. Fluorouracil drugs and pyrimidine nucleotides and their derivatives have a synergistic antitumor effect; combined use can reduce the concentration of single drugs and achieve better antitumor efficacy, while reducing toxic side effects.

The application discloses a recombinant oncolytic virus targeting CD317 gene and application thereof in anti-tumor, and belongs to the technical field of tumor treatment. The recombinant oncolytic virus comprises a CD317 inhibitor and an oncolytic virus, and is formed by integrating the CD317 inhibitor into the oncolytic virus genome. The CD317 inhibitor is a substance capable of inhibiting CD317 gene expression or targeting degradation of CD317 protein function, and is selected from shRNA or siRNA targeting CD317. The application develops the oncolytic virus targeting knockdown of CD317 expression, inhibits tumor cell proliferation by reducing CD317 expression of tumor cells, reduces PD-L1 expression so as to break the immune escape mechanism, simultaneously enhances the killing sensitivity of tumor cells to CD8+ T cells, forms a synergistic effect with the oncolysis of the oncolytic virus, and the recombinant oncolytic virus has stronger in-vivo anti-tumor activity, thereby providing a new potential scheme for CD317-driven tumor treatment.

The application discloses an inhibitor for inhibiting KRAS phase separation to play an anti-tumor role and application, and relates to the fields of tumor molecular biology and targeted therapy.The application aims at solving the problems of limited effect, strong drug resistance and limited application range of KRAS tumor treatment methods, and the inhibitor is a statin.The KRAS protein can form a liquid condensate in cells, and the application discloses the mechanism of the KRAS protein in promoting KRAS protein processing, transportation and downstream signal activation, and further provides a technical scheme for inhibiting tumor growth and enhancing the therapeutic effect of a KRAS inhibitor by inhibiting the formation of KRAS condensates, so as to provide a new target and intervention approach for tumor treatment.

The application relates to the field of triple-negative breast cancer treatment and relates to synthesis of an acid-responsive amphiphilic liposome and application of the acid-responsive amphiphilic liposome in tumor treatment. A chemotherapeutic drug, a phospholipid, cholesterol and a polyethylene glycolized lipid are dissolved in an organic solvent chloroform, vacuum rotary evaporation is carried out under certain temperature and rotation rate, a water phase is added for hydration, a polypeptide nanogold cluster solution is added for ultrasonic treatment, then crushing, molecular sieve screening, dialysis and ultrafiltration are carried out to obtain a pH-sensitive liposome; in the preparation process, the phospholipid spontaneously forms a kind of biological membrane-like phospholipid bilayer membrane vesicle in water, and the chemotherapeutic drug and the nanogold cluster are wrapped in the vesicle. The pH-sensitive liposome can target the triple-negative breast cancer tumor site through pH response, can improve the solubility of the chemotherapeutic drug, can realize high-efficiency treatment effect of the drug at a low dose, can obviously reduce the toxic side effect of the chemotherapeutic drug, and can realize effective treatment of the triple-negative breast cancer.

The present invention provides a bispecific antibody comprising a first portion targeting PD-L1 and a second portion targeting IL-1, wherein the first portion comprises an anti-PD-L1 antibody or its antigen-binding fragment, and the second portion comprises the extracellular binding domain of the IL-1 receptor (IL-1R) or a variant thereof, or an anti-IL-1β antibody or its antigen-binding fragment. The invention also provides the use of the bispecific antibody in the treatment of tumors.

This application provides a method for preparing pH-responsive polyamino acid drug-loaded nanoparticles based on sarcosine and their application. Sar-NNCA, L-lysine-NCA, and L-phenylalanine-NCA are dissolved in anhydrous DMF and polymerized under argon protection with a hexamethyldisilazine initiator to obtain a polyamino acid block copolymer Sar-NNCA. 80 -Lys(Cbz) n -Phe 10 The crude product was deprotected under HBr / acetic acid and loaded with DOX to obtain Sar. 80 -Lys n -Phe 10 -DOX. This application describes the preparation of a pH-responsive polymer nanoplatform, Sar, by encapsulating doxorubicin in polysarcosine-polylysine-polyphenylalanine nanoparticles via Schiff base bonds. 80 -Lys n -Phe 10 -DOX is used for tumor treatment. These polyamino acid nanoparticles are spherical with an average particle size of approximately 200 nanometers, exhibiting pH-responsive properties, excellent cellular uptake capacity, and anti-tumor effects. In vitro experiments show that Sar... 80 -Lys n -Phe 10 The carrier material exhibits excellent biocompatibility. The newly synthesized Sar... 80 -Lys n -Phe 10 -DOX nanomicelles show promise as a drug delivery system for cancer treatment.

This invention belongs to the field of tumor treatment, specifically relating to the application of a CHK1 inhibitor in the preparation of drugs that weaken radiotherapy and chemotherapy resistance in nasopharyngeal carcinoma. This invention is the first to clearly demonstrate that F-circRM mediates radiotherapy and chemotherapy resistance by activating the CHK1 signaling pathway, enhancing the DNA damage repair capacity of nasopharyngeal carcinoma cells, and thus mediating the core mechanism. The CHK1 inhibitor can effectively block this pathway, significantly enhancing the sensitivity of nasopharyngeal carcinoma to radiotherapy and chemotherapy and reversing radiotherapy and chemotherapy resistance in in vitro multi-cell lines, patient-derived primary cells, and in vivo animal models. This invention also clarifies that F-circRM can serve as a biomarker for predicting the efficacy of radiotherapy and chemotherapy, providing a basis for stratification and individualized treatment plans for nasopharyngeal carcinoma patients, and has significant clinical value and broad application prospects.

This invention relates to the field of biotechnology, specifically to a TruC-T cell that secretes and expresses IL-7 and PF4 to enhance anti-tumor activity and targets uPAR, and its application. Interleukin-7 (IL-7) can effectively promote the development, survival, and proliferation of T cells, while platelet factor 4 (PF4 / CXCL4) can regulate the immune response and chemotactically attract leukocytes to specific sites; the synergistic effect of the two can enhance the anti-tumor function and persistence of T cells. Meanwhile, urokinase-type plasminogen activator receptor (uPAR) is highly expressed in various solid tumors and hematological malignancies, making it an ideal target for tumor therapy; TruC-T cells targeting uPAR can precisely act on tumor tissue, and combined with the immune-enhancing effects of IL-7 and PF4, can significantly improve the efficacy of anti-tumor immune responses, prolong the duration of therapeutic effects, and reduce tumor recurrence.

The application discloses a novel AIE photosensitizer and a preparation method and application thereof. The AIE photosensitizer of the application comprises TDQ shown in the following structural formula, has superior photo-thermal conversion performance and photodynamic performance, and can be used for preparing a tumor diagnosis reagent or a tumor treatment drug. The co-loading liposome of TDQ and a senescence-inducing molecule (Ali) can be used as a multi-modal light diagnosis and treatment agent to realize efficient delivery of drugs to tumor tissues, and the photo-thermal therapy and the photodynamic therapy based on TDQ not only induce cell apoptosis through oxidative stress and mitochondrial dysfunction, but also trigger cancer cell senescence and promote the secretion of SASPs, so that the anti-tumor immunity is significantly enhanced, and finally the growth of primary tumors, tumor recurrence and re-metastasis are inhibited. The material of the application has simple preparation process, low cost, and is suitable for scale production and clinical medical use.

The present invention relates to an EZH1 / 2 inhibitor, a preparation thereof, and a use thereof in anti-tumor therapy, specifically comprising a compound represented by formula I or formula II, or a deuterated compound, or a stereoisomer, or a pharmaceutically acceptable salt thereof, and further comprising a pharmaceutical composition of the compound, and a use of the foregoing as an EZH1 / 2 inhibitor in the preparation of medication for treating related diseases.

The present invention provides antibody-drug conjugates, as well as pharmaceutically acceptable salts, hydrates, solvates, stereoisomers or isotope-labeled forms thereof, pharmaceutical compositions comprising the same, and uses thereof for the treatment of tumors and methods for treating tumors.

The application discloses a kind of space-time controllable PROTAC based on photo-initiated in-situ generation and application thereof.The PROTAC is divided into two components: biorthogonal reaction group and the component of target protein ligand connection, biorthogonal reaction group and the component of E3 ubiquitin ligase ligand connection, can be synthesized in situ by light control PROTAC, for targeted protein degradation.It overcomes the difficulty of PROTAC molecule from scratch synthesis, synthesis step is complicated and the like, avoids the adverse pharmacological performance and toxic side effects caused by large molecular weight in traditional PROTAC design.At the same time, only after lightening, PROTAC molecule can be generated, the target protein is degraded, tumor cells are killed, off-target toxicity is avoided, and tumor treatment effect is realized.The method for generating protein hydrolysis targeting chimera by light triggering click provided by the application can controllably and efficiently synthesize PROTAC molecules with anticancer effect, and has the prospect of precise regulation of intracellular protein expression and treatment of tumor.

This invention discloses a high-definition imaging-based minimally invasive tumor treatment interventional device, belonging to the field of tumor treatment technology. It includes a main tube with a compression balloon at one end. A high-definition display screen is fixedly mounted on the top surface of the main tube via a mounting bracket. A stabilizing support accessory is threaded onto the external surface of the main tube for stable support of the device on human skin. An interventional drug delivery component is slidably installed inside the main tube for rapid delivery of external drugs. A control component is located inside the main tube on one side of the interventional drug delivery component. This invention, through the accompanying stabilizing support accessory, effectively improves the stability of the device during puncture intervention and provides support in various situations. Furthermore, it allows for adjustment of the device's angle and position according to operational needs during puncture intervention, effectively improving the puncture intervention effect.

The application discloses a high-safety tumor treatment preparation based on a prodrug-enzyme-neutralizing antibody three-system, and a preparation method and application thereof. The preparation comprises three core components: (a) a prodrug, which is coupled by an anti-tumor drug (such as doxorubicin) and cephalosporin; (b) an activating enzyme, such as beta-lactamase, which is specifically expressed in the tumor by phage, catalyzes the hydrolysis of the prodrug, and releases the active drug; and (c) a neutralizing antibody, such as an anti-doxorubicin monoclonal antibody, which can specifically bind and neutralize the active drug overflowing into the blood circulation. The application first integrates the precise killing strategy of "prodrug-local activation" and the safety strategy of "neutralizing antibody-systematic protection" into a complete treatment closed loop, utilizes the "differential neutralization" characteristics of the anti-doxorubicin antibody, effectively protects normal tissues from toxic damage under the premise of not affecting the local efficacy of the tumor, and significantly improves the therapeutic index of the chemotherapy drug, reduces the side effects such as cardiotoxicity and bone marrow suppression, and provides a new paradigm with high efficiency and safety for tumor treatment.

This invention belongs to the field of traditional Chinese medicine technology and discloses drugs and methods of administration for preventing and treating viral infections and tumors. The drugs for preventing and treating viral infections and tumors are divided into two components. By weight, component one includes 0.5-25 parts of ginseng, 1-20 parts of astragalus, 1-18 parts of gastrodia, 1-24 parts of earthworm, 1-26 parts of chuanxiong, 0.1-15 parts of salvia miltiorrhiza, 0.1-10 parts of borneol, 1-28 parts of notoginseng, 1-32 parts of pinellia, 0.1-14 parts of centipede, and 0.1-17 parts of leech. Component two includes 1.5-2.5 parts of borax, 0.5-1.5 parts of potassium nitrate, 1.5-2.5 parts of sal ammoniac, 2-4 parts of agarwood, 4-6 parts of malachite, and 2-4 parts of borneol. This invention combines prevention and treatment. For uninfected individuals, the first component spray can effectively prevent viral infection, while for confirmed patients, the second component powder can kill viruses and tumors, resulting in good therapeutic effects and preventing the disease from worsening and spreading.

The application discloses a derivative with mitochondrial RNA polymerase inhibition and anti-tumor activity and a preparation method thereof, discloses a pharmaceutical composition containing the derivative, and discloses application of the derivative or a pharmaceutical salt thereof or the composition containing the derivative in preparation of a medicine for inhibiting mitochondrial RNA polymerase and treating tumors. The compound, the derivative and the composition thereof have strong anti-cancer cell proliferation activity and strong tumor inhibition effect.

The application of poly(D-lactic acid) and poly(D-lactic acid-glycolic acid) copolymers in constructing micro / nanocarriers for antitumor drugs belongs to the field of biomedical polymer materials and nanomedicine. The antitumor drugs are small-molecule chemotherapeutic agents, small-molecule photosensitizers, small-molecule immunotherapeutic agents, and small-molecule radiosensitizers. The particle size of the poly(D-lactic acid) and poly(D-lactic acid-glycolic acid) copolymers is 10–5000 nm. The effective concentration of the poly(D-lactic acid) and poly(D-lactic acid-glycolic acid) copolymers is 1–500 mg / kg. The antitumor mechanism of the poly(D-lactic acid) and poly(D-lactic acid-glycolic acid) copolymers includes increasing the activity of effector T cells in the tumor microenvironment and increasing the concentration of cytokines such as IFN-γ at the tumor site. In the field of tumor therapy, PLA and PLGA materials composed of D-lactic acid have shown good effects in inhibiting tumor growth, prolonging the survival period of tumor-bearing mice, and activating antitumor immune responses.

This invention belongs to the field of nanocarrier and immunotherapy technology, specifically relating to a lipid nanoparticle targeting tumor-associated macrophages, a combined delivery method, and its application in tumor immunotherapy. The lipid nanoparticles targeting CD206 tumor-associated macrophages constructed in this invention are used for efficient in vivo delivery of multifunctional nucleic acid molecules, achieving immune regulation, gene editing, and anti-tumor therapy. This invention achieves targeted delivery and multifunctional synergistic effects through lipid particle design, nucleic acid sequence design, and in vitro and in vivo functional verification. Through in vivo delivery of ipLNPs, macrophages can simultaneously achieve: 1) expression of anti-PD-L1 antibodies, blocking immunosuppressive signals; 2) expression of HER2-CAR structures, enhancing phagocytosis and killing ability against tumors; and 3) remodeling of the tumor immune microenvironment through CRISPR / Cas9-mediated FN1 knockout. The lipid nanoparticles constructed using this invention can solve the problem of insufficient targeting of immune cells in the tumor microenvironment by traditional LNP delivery systems.

The application discloses a kind of synergistic antitumor porphyrin-based covalent organic framework heterojunction materials and preparation method thereof, belong to biological medicine technical field. 5,10,15,20-tetra (4-aminobenzene) -21H,23H-porphyrin and 2,5-divinyl benzene formaldehyde are added to organic solvent to carry out solvothermal reaction, and porphyrin-based covalent organic framework (pCOF) is obtained;pCOF is mixed with 1,2-ethanedithiol and heated to obtain thiolated modified pCOF;Thiolated modified pCOF is stirred with glutathione aqueous solution ultrasonically, then tetra-chloroauric acid is added to carry out reaction, and synergistic antitumor porphyrin-based covalent organic framework confined gold nanocluster heterojunction material, recorded as Au@pCOF, is obtained.The Au@pCOF prepared in the application can be used as a kind of biocompatible antitumor therapeutic agent, under the irradiation of 808 nm near-infrared light, active oxygen is efficiently generated and heat is released, photothermal and photodynamic synergistic enhancement is realized, tumor cells are significantly killed, and is used for space-time integration synergistic antitumor therapy.

The present application relates to the technical fields of biological medicine and cellular immunotherapy, and particularly relates to a signal conversion receptor targeting IL-10, an engineered macrophage and application thereof. The signal conversion receptor is composed of an extracellular domain and a transmembrane domain and an intracellular domain derived from TLR9, and the extracellular domain sequentially comprises a signal peptide, a HA tag and a specific binding domain of an IL-10 receptor alpha subunit from N-terminal to C-terminal. The present application further prepares an engineered macrophage SR CAR-M capable of specifically recognizing IL-10 and converting it into a TLR9 activation signal, which can induce macrophages to polarize to M1 type and has excellent phagocytosis and killing capacity for bladder cancer, breast cancer, lung cancer and melanoma cells, and can be used for preparing related tumor treatment drugs, overcoming the common problems of existing cell therapy, such as easy exhaustion, difficult infiltration and easy inhibition in solid tumors, and having significant clinical transformation potential.

The application belongs to the technical field of immunotherapy, and particularly relates to an antigen epitope peptide of a tumor cell high-expression antigen LY6K and application thereof. The technical problem to be solved by the application is to provide a new method for treating or clinically detecting a tumor high in LY6K expression. The technical scheme of the application is an antigen epitope peptide of a tumor cell high-expression antigen LY6K, the amino acid sequence of which is shown in SEQ ID No. 4. The application provides a LY6K antigen epitope peptide, and a pMHC complex or an antigen presenting cell directly loaded with the antigen epitope peptide can activate T cells. Therefore, the antigen epitope peptide can be applied to treatment or diagnosis of a tumor high in LY6K antigen expression.

To address the shortcomings of existing antitumor chemotherapy drugs, this invention provides a class of pyrazolopyridone derivatives and their preparation method. The compounds are structurally designed and modified using pyrazolopyridone as the parent core, resulting in a class of pyrazolopyridone derivatives (I) with good stability and significant antitumor effects: wherein: R 1 The compound is 4-methoxyphenyl,N-phenylbenzamide. This invention relates to the field of tumor treatment, specifically to a class of novel pyrazolopyridone derivatives with advantages such as structural stability and ease of preparation. These compounds can be used to treat diseases such as tumors and condyloma acuminata.

The invention provides a multispecific binding molecule, and relates to the technical field of biology. The multispecific binding molecule can bind a plurality of tumor associated antigens at the same time, and the tumor treatment effect can be improved.

The present application belongs to the technical field of image processing, and discloses an intelligent auxiliary processing system for abdominal cavity operation images, which comprises a data acquisition module, a data processing module, an intraoperative lesion diagnosis module, an intraoperative lesion analysis module, a clinical decision module and a scheme regulation module. The data acquisition module is used for acquiring laparoscope 3D optical molecular image data, RAL imaging data and device operation data. The data processing module is used for obtaining a comprehensive feature data set by processing the acquired laparoscope 3D optical molecular image data, RAL imaging data and device operation data. The intraoperative lesion diagnosis module is used for constructing an intraoperative lesion diagnosis model and predicting an optical feature index. The intraoperative lesion analysis module is used for comparing the predicted optical feature index with a preset optical feature index threshold value and judging whether there is a lesion. The clinical decision module is used for constructing a lesion degree prediction model and predicting a lesion severity. The scheme regulation module is used for implementing a corresponding tumor treatment scheme according to the lesion severity.

This invention belongs to the field of biomedical technology, specifically relating to triptolide liposomes (TP-lipo), their combined use, and their application in the prevention and treatment of tumors. To enhance the efficacy of triptolide in the treatment and prevention of tumors such as pancreatic cancer, cervical cancer, ovarian cancer, and colorectal cancer, and to improve its bioavailability and clinical application while reducing toxicity, this invention uses HSPC, DOPS, and cholesterol as liposome components to encapsulate triptolide monomers, thus preparing TP-lipo. Experiments have shown that TP-lipo exhibits anti-tumor activity: it directly kills tumor cells and reverses the immunosuppressive microenvironment, making it a potential drug for tumor treatment. TP-lipo, when used in combination with PD-1 antibodies, or in combination with radiotherapy, chemotherapy, or surgery, demonstrates a potent and synergistic anti-tumor effect with low toxicity. Therefore, the TP-lipo of this invention provides more clinical strategies for tumor treatment.

The present invention provides a composition comprising a novel shear-reducing biomaterial useful for the delivery of polypeptide therapeutic agents. [Solution] A shear-thinning hydrogel composition comprising gelatin, silicate nanoparticles, and a polypeptide therapeutic agent, wherein the gelatin, silicate nanoparticles, and therapeutic agent form a shear-thinning hydrogel. Preferably, a shear-thinning hydrogel composition is provided comprising about 1% (w / w) to about 5% (w / w) of gelatin and about 1% (w / w) to about 5% (w / w) of silicate nanoparticles.